Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-01-25
2011-01-25
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S388800
Reexamination Certificate
active
07875277
ABSTRACT:
The present invention relates to compositions and methods for detecting and inhibiting squamous cell carcinoma using agents that target the laminin 5 alpha 3 G4-G5 domain.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 6120991 (2000-09-01), Carter et al.
patent: 6294356 (2001-09-01), Jones et al.
patent: 7256001 (2007-08-01), Katayama et al.
patent: 2002/0076736 (2002-06-01), Findell et al.
patent: WO9010448 (1990-09-01), None
patent: WO9104753 (1991-04-01), None
patent: WO9604000 (1996-02-01), None
patent: WO0026342 (2000-05-01), None
patent: WO0187239 (2001-11-01), None
patent: 03/016907 (2003-02-01), None
Goldfinger, J Cell Science, 1999, 112:2615-2629.
Ahmed et al., “Chapter 39: Immunity to Viruses,” Fundamental Immunology, 4th edition, W.E. Paul, ed., Lippincott-Raven Publishers, 1999, pp. 1295-1334.
Alama et al., “Antisense oligonucleotides as therapeutic agents,” Pharmacol Res., 1997, 36(3):171-178.
Amano et al., “Bone morphogenetic protein 1 is an extracellular processing enzyme of the laminin 5 gamma 2 chain,” J. Biol. Chem, 2000, 275(30): 22728-22735.
Berndt et al., “Oral squamous cell carcinoma invasion is associated with a laminin-5 matrix re-organization but independent of basement membrane and hemidesmosome formation. clues from an in vitro invasion model,” Invasion Metastasis, 1997, 17(5):251-258.
Boado et al., “Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS,” J. Pharm. Sci., 1998, 87(11):1308-1315.
Cassidy et al., “Melanocytes adhere to and synthesize laminin-5 in vitro,” Exp. Dermatol., 1999, 8(3):212-221.
Chan et al., “Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid,” J Invest. Dermatol., 1997, 108(6):848-853.
Chen et al., “NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats,” J Invest. Dermatol., 1999, 112(2):177-183.
Cheng et al., “Self-assembly of laminin isoforms,” J Biol. Chem., 1997, 272(50):31525-31532.
Crooke, “Advances in understanding the pharmacological properties of antisense oligonucleotides,” Adv. Pharmacol., 1997, 40:1-49.
Dajee et al., “NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia,” Nature, 2003, 421(6923):639-643.
Diederichsen, “Alanyl-PNA homoduplex: A-T pairing with the N7-regioisomer of adenine,” Bioorg. Med. Chem. Lett., 1998, 8(2):165-168.
Fukushima et al., “Integrin alpha3beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells,” Int. J Cancer, 1998, 76(1):63-72.
Huse et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda,” Science, 1989, 246:1275-1281.
Jordan et al., “New hetero-oligomeric peptide nucleic acids with improved binding properties to complementary DNA,” Bioorg. Med. Chem. Lett., 1997, 7(6):687-690.
Jordan et al., “Synthesis of new building blocks for peptide nucleic acids containing monomers with variations in the backbone,” Bioorg. Med. Chem. Lett., 1997, 7(6):681-686.
Kirtschig et al., “Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5,” J Invest. Dermatol., 1995, 105(4):543-548.
Kumar et al., “Pyrrolidine nucleic acids: DNA/PNA oligomers with 2-hydroxy/aminomethyl-4-(thymin-1-yl)pyrrolidine-N-acetic acid,” Org. Lett., 2001, 3(9):1269-1272.
Lavrosky et al., “Therapeutic potential and mechanism of action of oligonucleotides and ribozymes,” Biochem. Mol. Med., 1997, 62(1):11-22.
Lee et al., “Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription,” Biochemistry, 1998, 37(3):900-910.
Li et al., “Laminin-10 is crucial for hair morphogenesis,” EMBO J, 2003, 22(10):2400-2410.
Maddox et al., “Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein,” J Exp Med, 1983, 158(4):1211-1226.
Marcus-Sekura, “Techniques for using antisense oligodeoxyribonucleotides to study gene expression,” Anal. Biochem., 1988, 172(2):289-295.
Marinkovich et al., “Basement membrane proteins kalinin and nicein are structurally and immunologically identical,” Lab. Invest., 1993, 69(3):295-299.
Marinkovich et al., “LAD-1 is absent in a subset of junctional epidermolysis bullosa patients,” J Invest. Dermatol., 1997, 109(3):356-359.
Marinkovich et al., “Prenatal diagnosis of Herlitz junctional epidermolysis bullosa by amniocentesis,” Prenat. Diagn., 1995, 15(11):1027-1034.
Marinkovich et al., “The anchoring filament protein kalinin is synthesized and secreted as a high molecular weight precursor,” J Biol. Chem., 1992, 267(25):17900-17906.
Marinkovich et al., “The dermal-epidermal junction of human skin contains a novel laminin variant,” J Cell Biol., 1992, 119(3):695-703.
Marinkovich, “The molecular genetics of basement membrane diseases,” Arch. Dermatol., 1993, 129 (12):1557-1565.
McGowan et al., “Laminins and human disease,” Microsc. Res. Tech., 2000, 51(3):262-279.
Meneguzzi et al., “Kalinin is abnormally expressed in epithelial basement membranes of Herlitz's junctional epidermolysis bullosa patients,” Exp. Dermatol., 1992, 1(5):221-229.
Miguel et al., “Establishment and characterization of cell line LSV5 that retains the altered adhesive properties of human junctional epidermolysis bullosa keratinocytes,” Exp. Cell Res., 1996, 224(2):279-290.
Miller, “Progress Toward Human Gene Therapy,” Blood, 1990, 76(2):271-278.
Mizushima et al., “Identification of integrin-dependent and -independent cell adhesion domains in COOH-terminal globular region of laminin-5 alpha 3 chain,” Cell Growth Differ., 1997, 8(9):979-987.
Morris et al., “A new peptide vector for efficient delivery of oligonucleotides into mammalian cells,” Nucleic Acids Res., 1997, 25(14):2730-2736.
Nielsen et al., “Peptide nucleic acid (PNA). A DNA mimic with a pseudopeptide backbone,” Chem. Soc. Rev., 1997,26(22):73-78.
Orlandi et al., “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,” Proc. Natl. Acad. Sci. USA, 1989, 86(10):3833-3837.
Ortiz-Urda et al., “Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue,” J Clin. Invest., 2003, 111(2):251-255.
O'Toole et al., “Laminin-5 inhibits human keratinocyte migration,” Exp. Cell Res., 1997, 233(2):330-339.
Pardridge et al., “Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood-brain barrier in vivo,” Proc. Natl. Acad. Sci. USA, 1995 92(12):5592-5596.
Pyke et al., “Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas,” Cancer Res., 1995 ,55(18):4132-4139.
Pyke, et al., “The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers,” Am. J Pathol., 1994, 145(4):782-791.
Rammensee et al., “Syfpeithi: database for MHC ligands and peptide motifs,” Immunogenetics, 1999, 50 (3-4):213-219.
Rossi et al., “Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents,” Antisense Res. Dev., 1991, 1(3):285-288.
Rossi, “Therapeutic antisense and ribozymes,” Br. Med. Bull., 1995, 51(1):217-225.
R
DiGiorgio, Esq. Jeanne M.
Halvorson Mark
Lahive & Cockfield LLP
Remillard, Esq. Jane E.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Compositions and methods for inhibiting squamous cell carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting squamous cell carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting squamous cell carcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694221